Annovis Bio announces trial design of their planned Phase 3 trial evaluating buntanetap (posiphen) in early #Parkinsons; 450 PD participants H&Y 1-3, randomized 1:1:1 (placebo, 10mg or 20mg once daily); MDS-UPDRS II & III as primary endpoints
Annovis Bio announces trial design of the... - Cure Parkinson's
Annovis Bio announces trial design of their planned Phase 3 trial evaluating buntanetap (posiphen) in early Parkinsons
3 Replies
•
Another good one
No locations posted here yet. clinicaltrials.gov/ct2/show...
Not what you're looking for?
You may also like...
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
endpoint=UPDRS II+III OFF
https://twitter.com/ScienceofPD/status/1545320232666923009
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
the EU sites yet.
https://www.prnewswire.com/news-releases/annovis-bio-announces-approval-for-europ
Annovis Bio Buntanetap
With the Buntanetap phase III trial dosing ending soon, I noticed that Annovis Bio stock is dropping
Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study
https://www.prnewswire.com/news-releases/annovis-bio-announces-two-presentations-at-the-adpd-2023-in
Related Posts
Anyone participating in the Buntanetap Phase 3 trial?
Anxious to hear any updates from Annovis Bio Butanetap phase 3 trial cohorts
Annovis Phase 3 Trial - has anyone participated?
Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months
Phase 3 trial of buntanetap for early-stage Parkinson’s nears end
